Yuji Mano

1.8k total citations · 1 hit paper
79 papers, 1.4k citations indexed

About

Yuji Mano is a scholar working on Oncology, Molecular Biology and Pharmacology. According to data from OpenAlex, Yuji Mano has authored 79 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 19 papers in Molecular Biology and 17 papers in Pharmacology. Recurrent topics in Yuji Mano's work include Pharmacogenetics and Drug Metabolism (15 papers), Drug Transport and Resistance Mechanisms (13 papers) and Cardiovascular and Diving-Related Complications (9 papers). Yuji Mano is often cited by papers focused on Pharmacogenetics and Drug Metabolism (15 papers), Drug Transport and Resistance Mechanisms (13 papers) and Cardiovascular and Diving-Related Complications (9 papers). Yuji Mano collaborates with scholars based in Japan, United States and United Kingdom. Yuji Mano's co-authors include Keiichirou Nemoto, Hidetaka Kamimura, Takashi Usui, Kazutomi Kusano, Kenji Kita, Osamu Takenaka, Saburo Higuchi, Muneo Aoyama, Haruhiko Abe and Toshio Okudera and has published in prestigious journals such as Scientific Reports, Journal of Bacteriology and Journal of Applied Physiology.

In The Last Decade

Yuji Mano

74 papers receiving 1.3k citations

Hit Papers

The pathway of auxin biosynthesis in plants 2012 2026 2016 2021 2012 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The pathway of auxin biosynthesis in plants
    2012 468 citations Yuji Mano et al. profile →

Peers

Yuji Mano
Guillermo Elizondo Mexico
Wolfgang Kaufmann Germany
Katsuhiko Yoshizawa Japan
Adriana Brondani da Rocha Brazil
Sung Su Yea South Korea
Yali Lv China
Pan Chen China
Barry L. Yano United States
Robert E. Larson United States
Donggeun Sul South Korea
Guillermo Elizondo Mexico
Yuji Mano
Citations per year, relative to Yuji Mano Yuji Mano (= 1×) peers Guillermo Elizondo

Countries citing papers authored by Yuji Mano

Since Specialization
Citations

This map shows the geographic impact of Yuji Mano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuji Mano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuji Mano more than expected).

Fields of papers citing papers by Yuji Mano

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuji Mano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuji Mano. The network helps show where Yuji Mano may publish in the future.

Co-authorship network of co-authors of Yuji Mano

This figure shows the co-authorship network connecting the top 25 collaborators of Yuji Mano. A scholar is included among the top collaborators of Yuji Mano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuji Mano. Yuji Mano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Yamazaki, Kazuto, Kenji Kubara, Yuji Mano, et al.. (2025). Species-specific gene expression manipulation in humanized livers of chimeric mice via siRNA-encapsulated lipid nanoparticle treatment. Molecular Therapy — Methods & Clinical Development. 33(2). 101466–101466. 2 indexed citations
3.
Aoyama, Muneo & Yuji Mano. (2024). Nonclinical immunogenicity assessment of E3112, a recombinant human hepatocyte growth factor, and its impact on pharmacokinetics in rats and monkeys. Journal of Pharmaceutical and Biomedical Analysis. 252. 116504–116504.
4.
Mano, Yuji, et al.. (2024). Pharmacokinetic profiles of methylcobalamin in rats after multiple administration routes by a simple LC-MS/MS assay with a small volume of plasma. Journal of Pharmacological and Toxicological Methods. 129. 107552–107552.
5.
Aoyama, Muneo & Yuji Mano. (2024). Nonclinical pharmacokinetics of E3112, a recombinant human hepatocyte growth factor, in rats and monkeys by a simple ELISA kit assay. Journal of Pharmacological and Toxicological Methods. 128. 107541–107541. 1 indexed citations
6.
Kikuchi, Kiyomi, et al.. (2024). Development of the Complement C5 Assay by LC–MS/MS in Monkey Serum and Comparison with Enzyme-Linked Immunosorbent Assay. ACS Omega. 9(6). 6797–6802. 2 indexed citations
7.
8.
Aoyama, Muneo & Yuji Mano. (2023). Quantification of anti-drug antibodies against E6011, an anti-fractalkine monoclonal antibody, in monkey and human serum, by an electrochemiluminescence assay. Journal of Pharmacological and Toxicological Methods. 124. 107470–107470. 5 indexed citations
9.
10.
Sano, Takuya, et al.. (2023). A Simple UPLC-MS/MS Assay of Rifampin in a Small Volume of Human Plasma. ACS Omega. 8(39). 36261–36268. 3 indexed citations
11.
Niwa, Yuki, Kimiyo Tabata, Yuji Mano, et al.. (2023). Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody. Molecular Cancer Therapeutics. 22(4). 499–510. 8 indexed citations
12.
Sano, Takuya, et al.. (2022). A validated UPLC-MS/MS assay of E7090, a novel selective inhibitor of fibroblast growth factor receptors, in human plasma and urine. Journal of Pharmaceutical and Biomedical Analysis. 225. 115216–115216. 1 indexed citations
13.
14.
Mano, Yuji, et al.. (2022). A simple UPLC-MS/MS assay with a core-shell column for the determination of exemestane in human plasma for clinical application. European Journal of Mass Spectrometry. 28(3-4). 94–103. 2 indexed citations
15.
Ishida, T., et al.. (2020). Quantitative and qualitative application of a novel capillary microsampling device, Microsampling Wing™ (MSW), using antiepileptic drugs in rats. Journal of Pharmaceutical and Biomedical Analysis. 194. 113788–113788. 12 indexed citations
16.
Mano, Yuji & Hitoshi Mizuo. (2019). Minimal impact of hepatic and renal impairment on plasma protein binding of lenvatinib, and identification of its major plasma binding protein. Biopharmaceutics & Drug Disposition. 40(8). 307–311. 6 indexed citations
17.
Mano, Yuji. (2018). LC–MS-MS Determination of Oxcarbazepine and an Active Metabolite in Human Plasma for Clinical Application. Journal of Chromatographic Science. 56(8). 687–694. 6 indexed citations
18.
Kita, Kenji, et al.. (2018). Application of a Volumetric Absorptive Microsampling Device to a Pharmacokinetic Study of Tacrolimus in Rats: Comparison with Wet Blood and Plasma. European Journal of Drug Metabolism and Pharmacokinetics. 44(1). 91–102. 26 indexed citations
19.
Aoyama, Muneo & Yuji Mano. (2018). Application of an electrochemiluminescence assay for quantification of E6011, an antifractalkine monoclonal antibody, to pharmacokinetic studies in monkeys and humans. Journal of Clinical Laboratory Analysis. 33(1). e22625–e22625. 7 indexed citations
20.
Kita, Kenji, et al.. (2018). A dried blood spot assay with UPLC–MS/MS for the simultaneous determination of E6005, a phosphodiesterase 4 inhibitor, and its metabolite in human blood. Journal of Pharmaceutical and Biomedical Analysis. 157. 208–216. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Guillermo Elizondo Breakdown of academic impact, for papers by Wolfgang Kaufmann Breakdown of academic impact, for papers by Katsuhiko Yoshizawa Breakdown of academic impact, for papers by Adriana Brondani da Rocha Breakdown of academic impact, for papers by Sung Su Yea Breakdown of academic impact, for papers by Yali Lv Breakdown of academic impact, for papers by Pan Chen Breakdown of academic impact, for papers by Barry L. Yano Breakdown of academic impact, for papers by Robert E. Larson Breakdown of academic impact, for papers by Donggeun Sul
Rankless by CCL
2026